My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Amgen (NQ:AMGN)

336.74 +0.74 (+0.22%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9

...

60 61 Next >

Healthcare Staffing Giant AMN Healthcare Soars Amidst Landmark Drug-Pricing Agreement

September 30, 2025

New York, NY – September 30, 2025 – AMN Healthcare Services (NYSE: AMN), a leading provider of healthcare staffing solutions, witnessed a significant upward movement in its stock today, reflecting a...

Via MarketMinute

Topics Government

Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge

September 30, 2025

Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing...

Via MarketMinute

Topics Economy Government World Trade

Amgen Announces $650M Expansion Of US Manufacturing Network After Trump’s Pharma Tariff Announcement ↗

September 26, 2025

Via Stocktwits

Topics Government

How Is The Market Feeling About Amgen? ↗

September 17, 2025

Via Benzinga

Repligen, BrightSpring Health Services, Danaher, Thermo Fisher, and Amgen Shares Skyrocket, What You Need To Know

September 30, 2025

A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.

Via StockStory

Topics Government

Marjorie Taylor Greene Loads Up On Six-Figure Treasury Bill— Diversifies Portfolio With Bitcoin ETF, Tech Stocks ↗

September 30, 2025

Rep. Marjorie Taylor Greene's latest trades reveal a six-figure Treasury Bill buy, plus new stakes in tech stocks and a Bitcoin ETF.

Via Benzinga

Topics ETFs

Want Decades of Passive Income? Buy This Index Fund and Hold It Forever ↗

September 29, 2025

Dividend stocks can be a more predictable stream of income for investors.

Via The Motley Fool

Topics ETFs Stocks

Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Program ↗

September 29, 2025

The announcement from the group coincides with the deadline set by President Trump for 17 pharmaceutical companies to reduce drug prices in the U.S. to the levels paid by other developed countries.

Via Stocktwits

Topics Government

Why the Schwab U.S. Dividend Equity ETF Could Be a Top Choice for Dividend Investors in 2025 ↗

September 28, 2025

Instead of choosing just one or two stocks, buy a bunch of quality dividend-payers with a single ETF.

Via The Motley Fool

Topics ETFs Stocks

Amgen Expands US Manufacturing Network Amid New Tariff Policy ↗

September 26, 2025

Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network.

Via Benzinga

Topics Government World Trade

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

President Donald Trump threatened 100% tariffs on some drug imports.

Via Investor's Business Daily

Topics ETFs Government World Trade

Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility

September 26, 2025

September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025....

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

The Analyst Verdict: Amgen In The Eyes Of 8 Experts ↗

September 26, 2025

8 analysts have shared their evaluations of Amgen (NASDAQ: AMGN) during the recent three months, expressing a mix of bullish and bearish perspectives.

Via Benzinga

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

European Advisory Panel Recommends Two AstraZeneca Drugs For Approval ↗

September 22, 2025

AstraZeneca and Amgen secure CHMP support for Tezspire in nasal polyps and Koselugo in neurofibromatosis after strong Phase 3 trial results.

Via Benzinga

Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market

September 22, 2025

The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a...

Via MarketMinute

Topics Economy Intellectual Property

Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance

September 22, 2025

Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Eli Lilly's Ascent: A New Era in Obesity Treatment Driven by Zepbound and Orforglipron

September 22, 2025

Eli Lilly and Company (NYSE: LLY) has reported a stellar second quarter for 2025, significantly exceeding market expectations and cementing its position as a dominant force in the burgeoning obesity...

Via MarketMinute

Topics Economy

The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market

September 19, 2025

The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Why Amgen (AMGN) Stock Is Trading Up Today

September 19, 2025

Shares of biotech company Amgen (NASDAQ:AMGN) jumped 3.4% in the afternoon session after a European regulatory body recommended approving its drug, Uplizna, for treating a rare autoimmune disorder.

Via StockStory

Topics Artificial Intelligence

Friday's session: top gainers and losers in the S&P500 index ↗

September 19, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Via Chartmill

Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections

September 19, 2025

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

GLP-1 Titans Clash: Eli Lilly Challenges Novo Nordisk's Dominance in a Spiraling Market Battle

September 19, 2025

The pharmaceutical industry is witnessing an unprecedented showdown as Eli Lilly (NYSE: LLY) rapidly encroaches upon Novo Nordisk's (NYSE: NVO) long-held lead in the burgeoning GLP-1 (glucagon-like...

Via MarketMinute

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

Via MarketMinute

EMA Backs Amgen Drug For Rare Autoimmune Disorder ↗

September 19, 2025

European Medicines Agency's panel recommends expanding Amgen's Uplizna to treat IgG4-related disease, with trial data showing reduced flares and higher remission rates.

Via Benzinga

Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗

September 19, 2025

Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.

Via Chartmill

Uncover the latest developments among S&P500 stocks in today's session. ↗

September 19, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Via Chartmill

The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health

September 15, 2025

The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor...

Via MarketMinute

2 Healthcare Dividend Stocks to Buy and Hold ↗

September 14, 2025

These drugmakers have competitive yields and have increased their dividends at a good clip.

Via The Motley Fool

Topics Intellectual Property

The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment

September 12, 2025

The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

< Previous 1 2 3 4 5 6 7 8 9

...

60 61 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.